Recruiting NCT06308354
Colorectal Cancer Dataset in Xijing Hospital From 2011
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Prognostic Cancer Model, Chemotherapy, Nutrition Related Cancer. Basic parameters: 18 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.
Primary outcome measures
- overall survival [Time frame: from date of diagnosis until the date of death from any cause, assessed up to 120 months]
- DFS [Time frame: from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months]
Eligibility criteria
Inclusion criteria
- 1\. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
- 2\. Visit our center with complete medical records and pathological information;
- 3\. Colorectal cancer patients diagnosed between 2013 and 2023.
Exclusion criteria
- 1\. The patient has other colorectal malignancies other than adenocarcinoma;
- 2\. Malignant tumors adjacent to organs invading the colon and rectum;
- 3\. Malignant tumors from distant organs metastasize to the colon and rectum;
- 4\. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Fourth Military Medical University — Xi'an
Publications
- Cao S, Qiao Y, Wu L, Chen Q, Tian K, Li J, Xing C. Postoperative adjuvant chemotherapy in patients with stage II early onset colorectal cancer: exploration and discovery using real-world data and the SEER database. Front Oncol. 2025 May 30;15:1566569. doi: 10.3389/fonc.2025.1566569. eCollection 2025. PMID 40519292
Identifiers
NCT: NCT06308354 · CRC dataset